The presence of the JAK2 V617F mutation is associated with a higher haemoglobin and increased risk of thrombosis in essential thrombocythaemia

被引:121
作者
Cheung, B [1 ]
Radia, D [1 ]
Pantelidis, P [1 ]
Yadegarfar, G [1 ]
Harrison, C [1 ]
机构
[1] Guys & St Thomas NHS Fdn Trust, Dept Haematol, London SE1 7EH, England
关键词
essential thrombocythaemia; JAK2; thrombosis;
D O I
10.1111/j.1365-2141.2005.05858.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
引用
收藏
页码:244 / 245
页数:2
相关论文
共 6 条
[1]   Clinical implications of the JAK2 V617F mutation in essential thrombocythemia [J].
Antonioli, E ;
Guglielmelli, P ;
Pancrazzi, A ;
Bogani, C ;
Verrucci, M ;
Ponziani, V ;
Longo, G ;
Bosi, A ;
Vannucchi, AM .
LEUKEMIA, 2005, 19 (10) :1847-1849
[2]   Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders [J].
Baxter, EJ ;
Scott, LM ;
Campbell, PJ ;
East, C ;
Fourouclas, N ;
Swanton, S ;
Vassiliou, GS ;
Bench, AJ ;
Boyd, EM ;
Curtin, N ;
Scott, MA ;
Erber, WN ;
Green, AR .
LANCET, 2005, 365 (9464) :1054-1061
[3]   A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera [J].
James, C ;
Ugo, V ;
Le Couédic, JP ;
Staerk, J ;
Delhommeau, F ;
Lacout, C ;
Garçon, L ;
Raslova, H ;
Berger, R ;
Bennaceur-Griscelli, A ;
Villeval, JL ;
Constantinescu, SN ;
Casadevall, N ;
Vainchenker, W .
NATURE, 2005, 434 (7037) :1144-1148
[4]   Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders [J].
Jones, AV ;
Kreil, S ;
Zoi, K ;
Waghorn, K ;
Curtis, C ;
Zhang, LY ;
Score, J ;
Seear, R ;
Chase, AJ ;
Grand, FH ;
White, H ;
Zoi, C ;
Loukopoulos, D ;
Terpos, E ;
Vervessou, EC ;
Schultheis, B ;
Emig, M ;
Ernst, T ;
Lengfelder, E ;
Hehlmann, R ;
Hochhaus, A ;
Oscier, D ;
Silver, RT ;
Reiter, A ;
Cross, NCP .
BLOOD, 2005, 106 (06) :2162-2168
[5]   A gain-of-function mutation of JAK2 in myeloproliferative disorders [J].
Kralovics, R ;
Passamonti, F ;
Buser, AS ;
Teo, S ;
Tiedt, R ;
Passweg, JR ;
Tichelli, A ;
Cazzola, M ;
Skoda, RC .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (17) :1779-1790
[6]   Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis [J].
Levine, RL ;
Wadleigh, M ;
Cools, J ;
Ebert, BL ;
Wernig, G ;
Huntly, BJP ;
Boggon, TJ ;
Wlodarska, L ;
Clark, JJ ;
Moore, S ;
Adelsperger, J ;
Koo, S ;
Lee, JC ;
Gabriel, S ;
Mercher, T ;
D'Andrea, A ;
Fröhling, S ;
Döhner, K ;
Marynen, P ;
Vandenberghe, P ;
Mesa, RA ;
Tefferi, A ;
Griffin, JD ;
Eck, MJ ;
Sellers, WR ;
Meyerson, M ;
Golub, TR ;
Lee, SJ ;
Gilliland, DG .
CANCER CELL, 2005, 7 (04) :387-397